These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Steinberg EM; Cardoso GM; Martinez PE; Rubinow DR; Schmidt PJ Depress Anxiety; 2012 Jun; 29(6):531-40. PubMed ID: 22565858 [TBL] [Abstract][Full Text] [Related]
5. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Landén M; Erlandsson H; Bengtsson F; Andersch B; Eriksson E Neuropsychopharmacology; 2009 Feb; 34(3):585-92. PubMed ID: 18596686 [TBL] [Abstract][Full Text] [Related]
6. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Eriksson E; Ekman A; Sinclair S; Sörvik K; Ysander C; Mattson UB; Nissbrandt H J Clin Psychopharmacol; 2008 Apr; 28(2):195-202. PubMed ID: 18344730 [TBL] [Abstract][Full Text] [Related]
8. Selective serotonin reuptake inhibitors for premenstrual syndrome. Marjoribanks J; Brown J; O'Brien PM; Wyatt K Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD001396. PubMed ID: 23744611 [TBL] [Abstract][Full Text] [Related]
9. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. Yonkers KA; Kornstein SG; Gueorguieva R; Merry B; Van Steenburgh K; Altemus M JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969 [TBL] [Abstract][Full Text] [Related]
10. Symptom-onset treatment for women with premenstrual dysphoric disorder. Yonkers KA; Holthausen GA; Poschman K; Howell HB J Clin Psychopharmacol; 2006 Apr; 26(2):198-202. PubMed ID: 16633152 [TBL] [Abstract][Full Text] [Related]
11. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Steiner M; Hirschberg AL; Bergeron R; Holland F; Gee MD; Van Erp E Am J Obstet Gynecol; 2005 Aug; 193(2):352-60. PubMed ID: 16098854 [TBL] [Abstract][Full Text] [Related]
12. [Premenstrual dysphoric disorder (PMDD): Drug and psychotherapeutique management, a literature review]. Marais-Thomas H; Chapelle F; de Vaux-Boitouzet V; Bouvet C Encephale; 2024 Apr; 50(2):211-232. PubMed ID: 37821319 [TBL] [Abstract][Full Text] [Related]
14. Treatment of premenstrual dysphoric disorder with the GABA Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848 [TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD. Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781 [TBL] [Abstract][Full Text] [Related]
16. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Bixo M; Allard P; Bäckström T; Mjörndal T; Nyberg S; Spigset O; Sundström-Poromaa I Psychoneuroendocrinology; 2001 Aug; 26(6):551-64. PubMed ID: 11403977 [TBL] [Abstract][Full Text] [Related]
17. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols. Wu KY; Liu CY; Hsiao MC Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149 [TBL] [Abstract][Full Text] [Related]